Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 1/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.46 |
| ▸ | CTSS | P25774 | 9/20 | 0.45 |
| ▸ | AVPR1A | P37288 | 3/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | OXTR | P30559 | 2/20 | 0.41 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.41 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.40 |
| ▸ | PRKDC | P78527 | 1/20 | 0.40 |
| ▸ | DRD1 | P21728 | 2/20 | 0.40 |
| ▸ | DRD5 | P21918 | 2/20 | 0.40 |
| ▸ | C5AR1 | P21730 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4711335 | 0.82 | OPRM1 (0.58) | DRD2SLC6A4CYP3A4DRD1 | |
| SCHEMBL4903299 | 0.81 | CCR5 (0.48) | AVPR1ACYP3A4OXTR | |
| SCHEMBL4713988 | 0.79 | AVPR1A (0.42) | AVPR1ACYP3A4OXTR | |
| SCHEMBL4711858 | 0.77 | AVPR1A (0.44) | AVPR1ACYP3A4OXTR | |
| SCHEMBL4711541 | 0.76 | DRD2 (0.58) | DRD2SLC6A4CTSSHSD11B1 | |
| SCHEMBL4897490 | 0.76 | OPRM1 (0.52) | DRD2SLC6A4CTSS | |
| SCHEMBL4713565 | 0.75 | USP30 (0.47) | AVPR1ACYP3A4OXTR | |
| SCHEMBL4713593 | 0.75 | AVPR1A (0.45) | DRD2SLC6A4AVPR1AOXTR | |
| SCHEMBL4712455 | 0.74 | AVPR1A (0.44) | AVPR1AOXTR | |
| SCHEMBL5155966 | 0.74 | AVPR1A (0.48) | AVPR1AOXTR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080188478-A1 | Compounds Useful In Therapy | PFIZER INC. | 2008-08-07 | — | — | US | claimed |
| EP-1877399-A1 | TRIAZOLE DERIVATIVES AS VASOPRESSIN ANTAGONISTS | Pfizer Limited (GB) | 2008-01-16 | — | — | EP | claimed |
| WO-2006114706-A1 | TRIAZOLE DERIVATIVES AS VASOPRESSIN ANTAGONISTS | PFIZER LIMITED (GB) | 2006-11-02 | — | — | WO | claimed |
| US-20080188478-A1 | Compounds Useful In Therapy | PFIZER INC. | 2008-08-07 | — | — | US | disclosed |
| EP-1877399-A1 | TRIAZOLE DERIVATIVES AS VASOPRESSIN ANTAGONISTS | Pfizer Limited (GB) | 2008-01-16 | — | — | EP | disclosed |
| WO-2006114706-A1 | TRIAZOLE DERIVATIVES AS VASOPRESSIN ANTAGONISTS | PFIZER LIMITED (GB) | 2006-11-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080188478-A1 | Compounds Useful In Therapy | AVPR1A, AVPR1B, AVPR2 | DRD2 353/4885SLC6A4 1149/4885CTSS 1766/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.